2. Search Result
Search Result
Results for "

cc

" in MedChemExpress (MCE) Product Catalog:

329

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

7

Biochemical Assay Reagents

9

Peptides

8

Inhibitory Antibodies

14

Natural
Products

168

Recombinant Proteins

14

Isotope-Labeled Compounds

30

Antibodies

3

Click Chemistry

51

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0003
    Lenalidomide
    Maximum Cited Publications
    59 Publications Verification

    cc-5013

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Inflammation/Immunology Cancer
    Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
    Lenalidomide
  • HY-10984
    Pomalidomide
    30+ Cited Publications

    cc-4047

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Cancer
    Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
    Pomalidomide
  • HY-101488
    CC-885
    15+ Cited Publications

    		 Molecular Glues Ligands for E3 Ligase Cancer
    CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.
    CC-885
  • HY-129395
    Mezigdomide
    2 Publications Verification

    cc-92480

    		 E1/E2/E3 Enzyme Molecular Glues Apoptosis Cancer
    Mezigdomide (CC-92480), a cereblon E3 ubiquitin ligase modulating agent (CELMoD), acts as a molecular glue. Mezigdomide shows high affinity to cereblon, resulting in potent antimyeloma activity .
    Mezigdomide
  • HY-101291
    Iberdomide
    10+ Cited Publications

    cc-220

    		 Ligands for E3 Ligase Apoptosis Molecular Glues Inflammation/Immunology Cancer
    Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities .
    Iberdomide
  • HY-130800
    Eragidomide
    5+ Cited Publications

    cc-90009

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Inflammation/Immunology Cancer
    Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation .
    Eragidomide
  • HY-12085
    Apremilast
    5+ Cited Publications

    cc-10004

    		 Phosphodiesterase (PDE) Apoptosis TNF Receptor Inflammation/Immunology
    Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM .
    Apremilast
  • HY-158101
    BMS-986365
    1 Publications Verification

    cc-94676

    		 PROTACs Androgen Receptor Cancer
    BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC) .
    BMS-986365
  • HY-145449
    CC-885-CH2-PEG1-NH-CH3

    		E3 Ligase Ligand-Linker Conjugates ADC Payload Cancer
    CC-885-CH2-PEG1-NH-CH3 is a neoDegrader that can be used in the synthesis of Antibody neoDegrader Conjugate (AnDC). CC-885-CH2-PEG1-NH-CH3 is the toxic molecule of ADC, which can specifically degrade the target protein in cancer cells through the E3 ubiquitin ligase pathway .
    CC-885-CH2-PEG1-NH-CH3
  • HY-146237
    Golcadomide

    cc-99282

    		 Ligands for E3 Ligase Molecular Glues Cancer
    Golcadomide (CC-99282) is a potent and orally active CRBN E3 ligase modulator (CELMoD). Golcadomide interacts with the CRL4 CRBN E3 ubiquitin ligase substrate receptor CRBN, inducing the recruitment and ubiquitin-mediated proteasomal degradation of the transcription factors Ikaros and Aiolos. Golcadomide shows potential for research in cancer-related fields, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) .
    Golcadomide
  • HY-16962
    CC-115
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115
  • HY-129388B
    Pulrodemstat benzenesulfonate
    4 Publications Verification

    cc-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate

    		 Histone Demethylase Inflammation/Immunology Cancer
    Pulrodemstat (CC-90011) benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat benzenesulfonate is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
    Pulrodemstat benzenesulfonate
  • HY-100507
    Avadomide
    5+ Cited Publications

    cc 122

    		 E1/E2/E3 Enzyme Apoptosis Molecular Glues NF-κB Inflammation/Immunology Cancer
    Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities .
    Avadomide
  • HY-132304
    CC-90005

    		PKC Inflammation/Immunology
    CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50=4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression .
    CC-90005
  • HY-16956
    Onatasertib
    3 Publications Verification

    cc-223; ATG-008

    		 mTOR Apoptosis Cancer
    Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.
    Onatasertib
  • HY-138304
    CC-90001
    3 Publications Verification

    		 JNK Inflammation/Immunology
    CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .
    CC-90001
  • HY-137573
    Trotabresib
    1 Publications Verification

    cc-90010

    		 Epigenetic Reader Domain Cancer
    CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors .
    Trotabresib
  • HY-15495
    Tanzisertib
    10+ Cited Publications

    cc-930

    		 JNK Inflammation/Immunology
    Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC50s of 61/7/6 nM, respectively.
    Tanzisertib
  • HY-18012
    Spebrutinib
    15+ Cited Publications

    AVL-292; cc-292

    		 Btk Cancer
    Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC50 of 0.5 nM.
    Spebrutinib
  • HY-139504
    Gamcemetinib

    cc-99677

    		 MAPKAPK2 (MK2) Inflammation/Immunology
    Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .
    Gamcemetinib
  • HY-133073
    CCR7 Ligand 1
    3 Publications Verification

    ccR7-Cmp2105

    		 CCR Ligands for Target Protein for PROTAC Cancer
    CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM .
    CCR7 Ligand 1
  • HY-P99496
    Cendakimab
    1 Publications Verification

    RPC 4046; ABT 308; cc-93538

    		 Interleukin Related Inflammation/Immunology
    Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
    Cendakimab
  • HY-P99430
    Alnuctamab

    EM901; cc-93269

    		 CD3 Inflammation/Immunology Cancer
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Alnuctamab
  • HY-13022
    CC-401 hydrochloride
    5+ Cited Publications

    cc401 HCl

    		 JNK Cancer
    CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
    CC-401 hydrochloride
  • HY-16962A
    CC-115 hydrochloride
    2 Publications Verification

    		 DNA-PK mTOR Cancer
    CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
    CC-115 hydrochloride
  • HY-153698
    CC-3060

    		Molecular Glues Ligands for E3 Ligase Cancer
    CC-3060 is a molecular glue modulator targeting Cereblon (CRBN) E3 ubiquitin ligase and ZBTB16 degrader with a DC50 of 0.47 nM in HT-1080 cells. CC-3060 engages structural degrons on ZBTB16’s ZnF1 or ZnF3 domains for fusion protein substrates. CC-3060 can be used for the research of acute promyelocytic leukemia .
    CC-3060
  • HY-13022A
    CC-401
    5+ Cited Publications

    		 JNK Cancer
    CC-401 is a potent inhibitor of all three forms of JNK with Ki of 25 to 50 nM.
    CC-401
  • HY-112570
    CC-90003
    1 Publications Verification

    		 ERK Cancer
    CC-90003 is an irreversible and selective inhibitor of ERK 1/2 with antitumor activity.
    CC-90003
  • HY-139188
    CC260

    		PI5P4K Metabolic Disease Cancer
    CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with Kis of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research .
    CC260
  • HY-108709
    CC-671
    1 Publications Verification

    		 CDK Cancer
    CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
    CC-671
  • HY-147263
    Dovramilast

    cc-11050

    		 Phosphodiesterase (PDE) Infection Inflammation/Immunology
    Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB) .
    Dovramilast
  • HY-P990033
    Anzurstobart

    cc-95251; BMS-986351

    		 CD47 Cancer
    Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
    Anzurstobart
  • HY-P99172
    CC-90002

    		CD47 Interleukin Related Cancer
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
    CC-90002
  • HY-A0003B
    Lenalidomide hemihydrate
    Maximum Cited Publications
    59 Publications Verification

    cc-5013 hemihydrate

    		 Ligands for E3 Ligase Molecular Glues Apoptosis Cancer
    Lenalidomide hemihydrate (CC-5013 hemihydrate), a derivative of Thalidomide, acts as molecular glue. Lenalidomide hemihydrate is an orally active immunomodulator. Lenalidomide hemihydrate (CC-5013 hemihydrate) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide hemihydrate (CC-5013 hemihydrate) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
    Lenalidomide hemihydrate
  • HY-15301
    CC0651

    		E1/E2/E3 Enzyme Cancer
    CC0651 is an allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. CC0651 potently (IC50=1.72 μM) inhibits the ubiquitination of p27 Kip1, as confirmed by dose-response analysis.
    CC0651
  • HY-123215
    CC-17369

    7-Hydroxy pomalidomide; Pomalidomide metabolite M16

    		 Ligands for E3 Ligase Cancer
    CC-17369 (7-Hydroxy pomalidomide) is a metabolite of Pomalidomide. CC-17369 is the Pomalidomide -based cereblon (CRBN) ligand used in the recruitment of CRBN protein. CC-17369 can be connected to the ligand for protein by a linker to form PROTAC .
    CC-17369
  • HY-P99732
    Minretumomab
    1 Publications Verification

    cc-49

    		 Mucin Cancer
    Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
    Minretumomab
  • HY-153551
    HBED-CC-tris(tert-butyl ester)

    		Biochemical Assay Reagents Cancer
    HBED-CC-tris(tert-butyl ester) is a derivative of HBED-CC and a bifunctional chelator. HBED-CC-tris(tert-butyl ester) can be used in the research of radiolabeling and compounds for tumor-assisted diagnosis .
    HBED-CC-tris(tert-butyl ester)
  • HY-50081
    CCR2-RA-[R]
    4 Publications Verification

    		 CCR Inflammation/Immunology Endocrinology
    CCR2-RA-[R] is an allosteric antagonist of the C-C chemokine receptor type 2 (CCR2) with an IC50 of 103 nM.
    CCR2-RA-[R]
  • HY-177093
    Irafamdastat

    BMS-986368; cc-97489; ABX-1772

    		 MAGL FAAH Neurological Disease
    Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect .
    Irafamdastat
  • HY-157453
    CCR4 antagonist 4
    1 Publications Verification

    		 CCR Inflammation/Immunology
    CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC50 of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC50: 0.007 μM) and Ca 2+ mobilization (IC50: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .
    CCR4 antagonist 4
  • HY-163064
    CC-3240

    		Molecular Glues LRRK2 Cancer
    CC-3240 (compound 13) is a molecular glue degrader of CaMKK2 based on CC-8977, with the IC50 of 9 nM .
    CC-3240
  • HY-173614
    CC-647

    		Molecular Glues E1/E2/E3 Enzyme Cancer
    CC-647 is a molecular glue modulator targeting Cereblon (CRBN) E3 ubiquitin ligase. CC-647 promotes the interaction between CRBN and ZBTB16 as well as its oncogenic fusion protein RARα-ZBTB16 (with a DC50 of 103 nM). CC-647 is promising for research of ZBTB16-RARα-associated acute promyelocytic leukemia (APL) .
    CC-647
  • HY-A0003R
    Lenalidomide (Standard)

    cc-5013 (Standard)

    		 Reference Standards Ligands for E3 Ligase Molecular Glues Apoptosis Inflammation/Immunology Cancer
    Lenalidomide (Standard) is the analytical standard of Lenalidomide. This product is intended for research and analytical applications. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells .
    Lenalidomide (Standard)
  • HY-145449A
    CC-885-CH2-PEG1-NH-CH3 TFA

    		E3 Ligase Ligand-Linker Conjugates ADC Payload Cancer
    CC-885-CH2-PEG1-NH-CH3 TFA is a new degrader that can be used to synthesize antibody-based novel degrader conjugated active molecules (AnDC). CC-885-CH2-PEG1-NH-CH3 TFA is the toxic molecule of ADC, which can specifically degrade the target protein in cancer cells through the E3 ubiquitin ligase pathway .
    CC-885-CH2-PEG1-NH-CH3 TFA
  • HY-129388A
    Pulrodemstat
    4 Publications Verification

    cc-90011; LSD1-IN-7

    		 Histone Demethylase Inflammation/Immunology Cancer
    Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
    Pulrodemstat
  • HY-10984R
    Pomalidomide (Standard)

    cc-4047 (Standard)

    		 Reference Standards Ligands for E3 Ligase Molecular Glues Apoptosis Cancer
    Pomalidomide (Standard) is the analytical standard of Pomalidomide. This product is intended for research and analytical applications. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
    Pomalidomide (Standard)
  • HY-123324
    Pomalidomide-5-OH

    5-Hydroxy pomalidomide; cc-17368

    		 Ligands for E3 Ligase Cancer
    Pomalidomide-5-OH (5-hydroxy pomalidomide) is the Pomalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Pomalidomide-5-OH can be connected to the ligand for protein by a linker to form PROTAC .
    Pomalidomide-5-OH
  • HY-10984S2
    Pomalidomide-d4

    cc-4047-d4

    		 Isotope-Labeled Compounds Apoptosis Ligands for E3 Ligase Molecular Glues Cancer
    Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
    Pomalidomide-d4
  • HY-12085S
    Apremilast-d5

    cc-10004-d5

    		 Phosphodiesterase (PDE) TNF Receptor Apoptosis Inflammation/Immunology
    Apremilast-d5 is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC50 of 104 nM .
    Apremilast-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: